

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Sokawa & Liu

APPLICATION No.: Unassigned

FILED: Concurrently Herewith

FOR: **METHOD OF TREATMENT USING
INTERFERON-TAU**

EXAMINER: Unassigned

ART UNIT: Unassigned

**Information Disclosure Statement Accompanying
Petition to Make Special**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed concurrent with a Petition to Make Special. It is also being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 C.F.R. § 1.97(b)].

The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application. The references most pertinent to the presently pending claims are discussed and distinguished in the accompanying Statement Regarding Preexamination Search and the Preliminary Amendment.

2. Cited Information

☒ Copies of the following references are enclosed:

☒ The following cite nos.: 10, 12, 14, 17-19, 21, 23-24, 27, 34-37, 46, 51, 55, 59, 62-64, 66, 69-72, 77, 79, and 85.

☒ Copies of the following references can be found in parent U.S. Application No. 09/910,406:

☒ The following cite nos.: 20, 22, 30-31, 38-42, 44-45, 47-50, 52-53, 58, 60-61, 65, 67-68, and 81-84.

- ☒ Copies of the following references can be found in parent U.S. Application No. 10/346,269:
 - ☒ The following cite nos.: 25-26, 28-29, 32-33, 43, 54, 56-57, 73-76, 78, and 80.
- ☒ This application was filed after 30 June 2003, therefore no copies of U.S. patents or published applications are required (See Notice of Deputy Commissioner Kunin on 11 July 2003). However, copies of U.S. patents discussed in the accompanying Statement Regarding Preexamination Search and the Preliminary Amendment are enclosed for the Examiner's convenience.

3. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

Respectfully submitted,

Date: 21 November 2003

Judy M. Mohr
Judy M. Mohr
Registration No. 38, 563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	Unassigned
				Confirmation Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Sokawa & Liu
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	5	Attorney Docket No.	55600-8013.US01

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1	4,683,195		Mullis, et al.	07/28/87	
	2	4,683,202		Mullis	07/28/87	
	3	4,766,068		Oeda, et al.	08/23/88	
	4	4,769,238		Rutter	09/06/88	
	5	5,019,382		Cummins, Jr.	05/28/91	
	6	5,372,808		Blatt & Taylor	12/13/94	
	7	5,438,040		Ekwuribe	08/01/95	
	8	5,738,845		Imakawa	04/14/98	
	9	5,882,640		Cummins	03/16/99	
	10	5,906,816		Soos, et al.	05/25/99	
	11	5,910,304		Cummins	06/08/99	
	12	5,958,402		Bazer, et al.	09/28/99	
	13	6,036,949		Richards & Sherwood	03/14/00	
	14	6,060,450		Soos, et al.	05/09/00	
	15	6,191,105		Ekwuribe, et al.	02/20/01	
	16	6,346,243		Brod	02/12/02	
	17	6,372,206		Soos, et al.	04/16/02	

FOREIGN PATENT DOCUMENTS								
Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	18	PCT	WO 90/09806		Bazer & Johnson	09/07/90		
	19	PCT	WO 94/10313		Bazer, et al.	05/11/94		
	20	PCT	WO 00/78266		Pontzer, et al.	12/28/00		
	21	PCT	WO 96/28183		Soos, et al.	09/19/96		
	22	PCT	WO 96/35789		Bazer, et al.	11/14/96		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	Unassigned
				Confirmation Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Sokawa & Liu
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	5	Attorney Docket No.	55600-8013.US01

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	23	Adah, S.A., et al., <i>Current Medicinal Chemistry</i> <u>8</u> :1189-1212, (2001).	
	24	Alexenko, A.P., et al., <i>Journal of Interferon and Cytokine Research</i> <u>17</u> :769-779, (1997).	
	25	Amidon, G.L., et al., <i>Peptide and Protein Drug Delivery, Alfred Benzon Symposium</i> <u>43</u> :146-152, (1998).	
	26	Bayley, D., et al., <i>J Pharm Pharmacol</i> <u>47</u> :721-724, (1995).	
	27	Bernkop-Schnürch, A. and Gilge, B., <i>Drug Development and Industrial Pharmacy</i> <u>26</u> (2):107-113, (2000).	
	28	Bocci, V., <i>Journal of Biological Regulators and Homeostatic Agents</i> <u>4</u> (2):81-83, (1990).	
	29	Bocci, V., <i>Journal of Interferon and Cytokine Research</i> <u>19</u> :859-861, (1999).	
	30	Bartol, F.F., et al., <i>Biology of Reproduction</i> <u>33</u> :745-759 abstract only (1985).	
	31	Bazer, F.W. and Johnson, H.M., <i>AJRI</i> <u>26</u> :19-22 (1991).	
	32	Brod, S.A., et al., <i>Neurology</i> <u>44</u> :1144-1148, (1994).	
	33	Brod, S.A., et al., <i>Journal of Interferon and Cytokine Research</i> <u>15</u> :115-122, (1995).	
	34	Brod, S.A., <i>Arch Neurol</i> <u>54</u> :1300-1302, (1997).	
	35	Brod, S.A., et al., <i>Diabetologia</i> <u>41</u> :1227-1232, (1998).	
	36	Brod, S.A., <i>Journal of Interferon and Cytokine Research</i> <u>19</u> :841-852, (1999).	
	37	Castelli, J., et al., <i>Biomed & Pharmacother</i> <u>52</u> :386-390, (1998).	
	38	Choo, Q.-L., et al., <i>Science</i> <u>244</u> :359-362 (1989).	
	39	Choo, Q.-L., et al., <i>Proc. Natl. Acad. Sci. USA</i> , <u>88</u> :2451-2455 (1991).	
	40	Clayette, P., et al., <i>Pathologie Biologique</i> , <u>47</u> (4):553-559 (1999).	
	41	Cotler, S.J., et al., <i>Journal of Viral Hepatitis</i> <u>7</u> :211-217 (2000).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	Unassigned
				Confirmation Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Sokawa & Liu
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket No.	55600-8013.US01
Sheet	3	of	5		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	42	Cross, J.C., <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> <u>88</u> :3817-3821 (1991).		
	43	Dianzani, F., <i>Journal of Interferon Research</i> pps. 109-118, (1992).		
	44	Dieperink, E., <i>et al.</i> , <i>Am. J. Psychiatry</i> <u>157</u> :867-876 (2000).		
	45	Ecker, D.J., <i>et al.</i> , <i>Journal of Biological Chemistry</i> <u>264</u> (13):7715-7719 (1989).		
	46	Eiamtrakarn, S., <i>et al.</i> , <i>Biomaterials</i> <u>23</u> :145-152, (2002).		
	47	Gnatek, G.G., <i>et al.</i> , <i>Biology of Reproduction</i> <u>41</u> :655-663 (1989).		
	48	Helmer, S.D., <i>et al.</i> , <i>J. Reprod. Fert.</i> , <u>79</u> :83-91 (1987).		
	49	Imakawa, K., <i>et al.</i> , <i>Nature</i> , <u>330</u> :377-379 (1987).		
	50	Imakawa, K., <i>et al.</i> , <i>Molecular Endocrinology</i> , <u>3</u> :127-139 (1989).		
	51	Jacobs, B.L., <i>et al.</i> , <i>Virology</i> <u>219</u> :339-349, (1996).		
	52	Jarpe, M.A., <i>et al.</i> , <i>Protein Engineering</i> <u>7</u> (7):863-867 (1994).		
	53	Jiménez-Sáenz, M., <i>et al.</i> , <i>Journal of Gastroenterology and Hepatology</i> <u>15</u> :567-569 (2000).		
	54	Johnson, H.M.47, <i>et al.</i> , <i>Scientific American</i> <u>270</u> (5):40-47, (1994).		
	55	Le Page, C., <i>et al.</i> , <i>Rev Immunogenetics</i> <u>2</u> :374-386, (2000).		
	56	Milstein, S.J., <i>et al.</i> , <i>Journal of Controlled Release</i> <u>53</u> :259-267, (1998).		
	57	Lawson, C.M. and Beilharz, M.W., <i>Journal of Interferon and Cytokine Research</i> <u>19</u> :863-867, (1999).		
	58	Magrin, S., <i>et al.</i> , <i>Hepatology</i> <u>19</u> :273-279 (1994).		
	59	Nakajima, A. and Sokawa, Y., <i>Journal of Interferon and Cytokine Research</i> <u>22</u> :397-402, (2002).		
	60	Ott, T.L., <i>et al.</i> , <i>Journal of Interferon Research</i> <u>11</u> :357-364 (1991).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	Unassigned
				Confirmation Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Sokawa & Liu
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	4	of	5	Attorney Docket No.	55600-8013.US01

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	61	Pawlotsky, J.-M., <i>et al.</i> , <i>Journal of Interferon and Cytokine Research</i> <u>15</u> :857-862 (1995).	
	62	Pontzer, C.H., <i>et al.</i> , <i>Biochem Biophys Res Communications</i> <u>152</u> (2):801-807, (1988).	
	63	Pontzer, C.H., <i>et al.</i> , <i>Pro Natl Acad Sci USA</i> <u>87</u> :5945-5949, (1990).	
	64	Reddy, S.M., <i>et al.</i> , <i>Drugs of Today</i> <u>35</u> (7):537-580, (1999).	
	65	Roberts, R.M., <i>et al.</i> , <i>Endocrine Review</i> <u>13</u> (3):432-452 (1992).	
	66	Roberts, R.M., <i>et al.</i> , <i>J Interferon Cytokine Res</i> <u>18</u> :805, (1998).	
	67	Saez-Royuela, F., <i>et al.</i> , <i>Hepatology</i> <u>10</u> (4):646 (1989).	
	68	Saito, H., <i>et al.</i> , <i>Journal of Viral Hepatitis</i> <u>7</u> :64-74 (2000).	
	69	Samuel, C.E., <i>Hokkaido J Med Sci</i> <u>69</u> (6):1339-1347, (1994).	
	70	Samuel, C.E., <i>Clinical Microbiology Reviews</i> <u>14</u> (4):778-809, (2001).	
	71	Satoh, Y.I., <i>et al.</i> , <i>J Interferon Cytokine Res</i> <u>19</u> :887-894, (1999).	
	72	Schröder, H.C., <i>et al.</i> , <i>Int J Biochem</i> <u>24</u> (1):55-63, (1992).	
	73	Shindo, M., <i>et al.</i> , <i>Hepatology</i> <u>9</u> (5):715-719, (1989).	
	74	Short, Jr., E.C., <i>et al.</i> , <i>Biology of Reproduction</i> <u>44</u> :261-268, (1991).	
	75	Singh, B.N., <i>Clin Pharmacokinet</i> <u>37</u> (3):213-255, (1999).	
	76	Sood, A. and Panchagnula, R., <i>Chem Rev</i> <u>101</u> :3275-3303, (2001).	
	77	Soos, J.M., <i>et al.</i> , <i>Journal of Neuroimmunology</i> <u>75</u> :43-50, (1997).	
	78	Stoll, B.R., <i>et al.</i> , <i>Journal of Controlled Release</i> <u>64</u> :217-228, (2000).	
	79	Takayama, S., <i>et al.</i> , <i>J Interferon Cytokine Res</i> <u>19</u> :895-900, (1999).	
	80	Thorbecke, G.J., <i>et al.</i> , <i>Arthritis & Rheumatism</i> <u>42</u> (1):110-118, (1999).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

